This is a summary of the European public assessment report (EPAR) for Emselex. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Emselex.
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.
Therapeutic Area (MeSH)
ATC Code
G04BD10
ATC Item
darifenacin
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| darifenacin hydrobromide | N/A | 氢溴酸达非那新 |
EMA Name
Emselex
Medicine Name
Emselex
Aliases
N/ANo risk management plan link.
